GSK picks up cancer drug discovery platform from Astex
GlaxoSmithKline (NYSE:GSK) is adding to its cancer drug discovery capabilities by picking up the epigenetics research program from drug partner Astex Pharmaceuticals (NASDAQ:ASTX). Oncology drug discovery and development company Astex will end its work on the the “Climb” collaboration and transfer the research work and assets to British pharma giant GSK, which has its U.S. […]